rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In the cohort of WDTC with distant metastasis, patients with wild-type BRAF and TERT promoter had a significantly higher response rate after radioiodine therapy (p = 0.024), whereas the BRAF V600E mutation was significantly correlated with progressive disease (p = 0.025).
|
26857243 |
2016 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Additionally, the presence of BRAFV600E was tested in peripheral mononuclear blood cells (PBMCs) as well as brain biopsies from LCH-ND patients, and the response to BRAF-V600E inhibitor was evaluated in 4 patients with progressive disease.
|
29624648 |
2018 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG.
|
28727518 |
2017 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Vemurafenib induces tumour regression in most patients with BRAF(V600E)-mutant melanoma; eventually, most experience progressive disease (PD).
|
25980594 |
2015 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumours containing wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response).
|
16880785 |
2006 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Additionally, the presence of BRAFV600E was tested in peripheral mononuclear blood cells (PBMCs) as well as brain biopsies from LCH-ND patients, and the response to BRAF-V600E inhibitor was evaluated in 4 patients with progressive disease.
|
29624648 |
2018 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumours containing wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response).
|
16880785 |
2006 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Vemurafenib induces tumour regression in most patients with BRAF(V600E)-mutant melanoma; eventually, most experience progressive disease (PD).
|
25980594 |
2015 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG.
|
28727518 |
2017 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In the cohort of WDTC with distant metastasis, patients with wild-type BRAF and TERT promoter had a significantly higher response rate after radioiodine therapy (p = 0.024), whereas the BRAF V600E mutation was significantly correlated with progressive disease (p = 0.025).
|
26857243 |
2016 |
rs775040765
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Regarding the efficacy of anti-EGFR therapy, the patient with an I326V mutation had progressive disease (+115%) despite no genetic alterations detected in the EGFR pathway that could drive resistance, suggesting an alternate resistance mechanism.
|
30463788 |
2018 |